M1i-124 treatment did reduce tumor levels of certain other MALT1-dependent NF-κB target genes at the 24-hour time point, including NFKBIZ and TNFA, while having no effect on genes including IRF4 and NFKBID (Figure 8D). The gene discussed is IRF4; the disease is neoplasm.